Lucia Gambuzza

A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026

In part 2 of a 2-part Q&A, John Berdahl, MD, weighs in on AI-driven IOL power calculation in challenging eyes, best practices for reducing posterior capsule opacification, and how surgical mission work abroad has shaped his approach in the OR.

In part 1 of a 2-part Q&A, John Berdahl, MD, discusses the widening global cataract surgical gap and examines emerging evidence linking cataract extraction to a reduced risk of dementia.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

Off-label use of laboratory-grade dye preparation found to harbor Sarocladium kiliense beyond the sterilizing capacity of standard filtration.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.